{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:51:07Z","timestamp":1794009067517,"version":"4.8.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T00:00:00Z","timestamp":1585353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Narcolepsy type 1 is hypothesized to be an autoimmune disease targeting the hypocretin\/orexin neurons in the hypothalamus. Ample genetic and epidemiological evidence points in the direction of a pathogenesis involving the immune system, but this is not considered proof of autoimmunity. In fact, it remains a matter of debate how to prove that a given disease is indeed an autoimmune disease. In this review, a set of commonly used criteria for autoimmunity is described and applied to narcolepsy type 1. In favor of the autoimmune hypothesis are data showing that in narcolepsy type 1 a specific adaptive immune response is directed to hypocretin\/orexin neurons. Autoreactive T cells and autoantibodies have been detected in blood samples from patients, but it remains to be seen if these T cells or antibodies are in fact present in the hypothalamus. It is also unclear if the autoreactive T cells and\/or autoantibodies can transfer the disease to healthy individuals or animals or if immunization with the proposed autoantigens can induce the disease in animal models. Most importantly, it is still controversial whether suppression of the autoimmune response can prevent disease progression. In conclusion, narcolepsy type 1 does still not fully meet the criteria for being classified as a genuine autoimmune disease, but more and more results are pointing in that direction.<\/jats:p>","DOI":"10.1093\/sleep\/zsaa055","type":"journal-article","created":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T16:35:15Z","timestamp":1585586115000},"source":"Crossref","is-referenced-by-count":29,"title":["Narcolepsy type 1: what have we learned from immunology?"],"prefix":"10.1093","volume":"43","author":[{"given":"Birgitte R","family":"Kornum","sequence":"first","affiliation":[{"name":"Department of Neuroscience, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,3,28]]},"reference":[{"key":"2020112501165020300_CIT0001","doi-asserted-by":"crossref","first-page":"16100","DOI":"10.1038\/nrdp.2016.100","article-title":"Narcolepsy","volume":"3","author":"Kornum","year":"2017","journal-title":"Nat Rev Dis Primers."},{"key":"2020112501165020300_CIT0002","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1371\/journal.pmed.0030297","article-title":"A proposed classification of the immunological diseases","volume":"3","author":"McGonagle","year":"2006","journal-title":"PLoS Med."},{"key":"2020112501165020300_CIT0003","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.autrev.2012.02.001","article-title":"Updated assessment of the prevalence, spectrum and case definition of autoimmune disease","volume":"11","author":"Hayter","year":"2012","journal-title":"Autoimmun Rev."},{"key":"2020112501165020300_CIT0004","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41586-018-0540-1","article-title":"T cells in patients with narcolepsy target self-antigens of hypocretin neurons","volume":"562","author":"Latorre","year":"2018","journal-title":"Nature."},{"key":"2020112501165020300_CIT0005","doi-asserted-by":"crossref","first-page":"E12323","DOI":"10.1073\/pnas.1818150116","article-title":"Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsy","volume":"115","author":"Luo","year":"2018","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2020112501165020300_CIT0006","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/s41467-019-08774-1","article-title":"CD8+ T cells from patients with narcolepsy and healthy controls recognize hypocretin neuron-specific antigens","volume":"10","author":"Pedersen","year":"2019","journal-title":"Nat Commun."},{"key":"2020112501165020300_CIT0007","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/sleep\/25.7.719","article-title":"Search for neuron-specific and nonneuron-specific antibodies in narcoleptic patients with and without HLA DQB1*0602","volume":"25","author":"Black","year":"2002","journal-title":"Sleep."},{"key":"2020112501165020300_CIT0008","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.biopsych.2005.04.026","article-title":"Studies of humoral immunity to preprohypocretin in human leukocyte antigen DQB1*0602-positive narcoleptic subjects with cataplexy","volume":"58","author":"Black","year":"2005","journal-title":"Biol Psychiatry."},{"key":"2020112501165020300_CIT0009","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/WNR.0b013e328010baad","article-title":"Antibodies in narcolepsy-cataplexy patient serum bind to rat hypocretin neurons","volume":"18","author":"Knudsen","year":"2007","journal-title":"Neuroreport."},{"key":"2020112501165020300_CIT0010","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jneuroim.2006.02.010","article-title":"Immunohistochemical screening for autoantibodies against lateral hypothalamic neurons in human narcolepsy","volume":"174","author":"Overeem","year":"2006","journal-title":"J Neuroimmunol."},{"key":"2020112501165020300_CIT0011","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/sleep\/29.5.633","article-title":"Detection of autoantibodies against hypocretin, hcrtrl, and hcrtr2 in narcolepsy: anti-Hcrt system antibody in narcolepsy","volume":"29","author":"Tanaka","year":"2006","journal-title":"Sleep."},{"key":"2020112501165020300_CIT0012","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jneuroim.2015.04.008","article-title":"Immunohistochemical screening for antibodies in recent onset type 1 narcolepsy and after H1N1 vaccination","volume":"283","author":"van der Heide","year":"2015","journal-title":"J Neuroimmunol."},{"key":"2020112501165020300_CIT0013","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1172\/JCI41366","article-title":"Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients","volume":"120","author":"Cvetkovic-Lopes","year":"2010","journal-title":"J Clin Invest."},{"issue":"7","key":"2020112501165020300_CIT0014","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/sleep\/33.7.869","article-title":"Anti-Tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy","volume":"33","author":"Kawashima","year":"2010","journal-title":"Sleep."},{"issue":"7","key":"2020112501165020300_CIT0015","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/sleep\/33.7.875","article-title":"Anti-Tribbles homolog 2 autoantibodies in Japanese patients with narcolepsy","volume":"33","author":"Toyoda","year":"2010","journal-title":"Sleep."},{"key":"2020112501165020300_CIT0016","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaut.2014.01.031","article-title":"A\/H1N1 antibodies and TRIB2 autoantibodies in narcolepsy patients diagnosed in conjunction with the Pandemrix vaccination campaign in Sweden 2009\u20132010","volume":"50","author":"Lind","year":"2014","journal-title":"J Autoimmun."},{"key":"2020112501165020300_CIT0017","doi-asserted-by":"crossref","first-page":"E3735","DOI":"10.1073\/pnas.1412189111","article-title":"Narcolepsy patients have antibodies that stain distinct cell populations in rat brain and influence sleep patterns","volume":"111","author":"Bergman","year":"2014","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"294","key":"2020112501165020300_CIT0018","doi-asserted-by":"crossref","first-page":"294ra105","DOI":"10.1126\/scitranslmed.aab2354","article-title":"Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2","volume":"7","author":"Ahmed","year":"2015","journal-title":"Sci Transl Med."},{"key":"2020112501165020300_CIT0019","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ebiom.2018.01.043","article-title":"Prostaglandin D2 receptor DP1 antibodies predict vaccine-induced and spontaneous narcolepsy type 1: large-scale study of antibody profiling","volume":"29","author":"Sadam","year":"2018","journal-title":"EbioMedicine."},{"key":"2020112501165020300_CIT0020","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1021\/acs.jproteome.6b00916","article-title":"Whole-proteome peptide microarrays for profiling autoantibody repertoires within multiple sclerosis and narcolepsy","volume":"16","author":"Zandian","year":"2017","journal-title":"J Proteome Res."},{"key":"2020112501165020300_CIT0021","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsw056","article-title":"Antibodies against hypocretin receptor 2 are rare in narcolepsy","volume":"40","author":"Giannoccaro","year":"2017","journal-title":"Sleep."},{"key":"2020112501165020300_CIT0022","doi-asserted-by":"crossref","first-page":"e0187305","DOI":"10.1371\/journal.pone.0187305","article-title":"Absence of anti-hypocretin receptor 2 autoantibodies in post pandemrix narcolepsy cases","volume":"12","author":"Luo","year":"2017","journal-title":"PLoS One."},{"key":"2020112501165020300_CIT0023","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0092-8674(00)81973-X","article-title":"Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation","volume":"98","author":"Chemelli","year":"1999","journal-title":"Cell."},{"key":"2020112501165020300_CIT0024","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0092-8674(00)81965-0","article-title":"The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene","volume":"98","author":"Lin","year":"1999","journal-title":"Cell."},{"key":"2020112501165020300_CIT0025","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0896-6273(00)00058-1","article-title":"Reduced number of hypocretin neurons in human narcolepsy","volume":"27","author":"Thannickal","year":"2000","journal-title":"Neuron."},{"key":"2020112501165020300_CIT0026","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/ana.24019","article-title":"Increase of histaminergic tuberomammillary neurons in narcolepsy","volume":"74","author":"Valko","year":"2013","journal-title":"Ann Neurol."},{"key":"2020112501165020300_CIT0027","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/nyas.12793","article-title":"Type 1 narcolepsy: a CD8(+) T cell-mediated disease?","volume":"1351","author":"Degn","year":"2015","journal-title":"Ann N Y Acad Sci."},{"key":"2020112501165020300_CIT0028","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jneuroim.2017.05.001","article-title":"Absence of autoreactive CD4+ T-cells targeting HLA-DQA1*01:02\/DQB1*06:02 restricted hypocretin\/orexin epitopes in narcolepsy type 1 when detected by EliSpot","volume":"309","author":"Kornum","year":"2017","journal-title":"J Neuroimmunol."},{"key":"2020112501165020300_CIT0029","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsw070","article-title":"CD4+ T-cell reactivity to orexin\/hypocretin in patients with narcolepsy type 1","volume":"40","author":"Ramberger","year":"2017","journal-title":"Sleep."},{"key":"2020112501165020300_CIT0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cellimm.2010.02.008","article-title":"Cytolytic CD4 cells: direct mediators in infectious disease and malignancy","volume":"262","author":"Brown","year":"2010","journal-title":"Cell Immunol."},{"key":"2020112501165020300_CIT0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13234-x","article-title":"In vivo clonal expansion and phenotypes of hypocretin-specific CD4+ T cells in narcolepsy patients and controls","volume":"10","author":"Jiang","year":"2019","journal-title":"Nat Commun."},{"key":"2020112501165020300_CIT0032","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1126\/science.7624779","article-title":"Induction of MHC class I genes in neurons","volume":"269","author":"Neumann","year":"1995","journal-title":"Science."},{"key":"2020112501165020300_CIT0033","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1038\/ncomms4633","article-title":"MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration","volume":"5","author":"Cebri\u00e1n","year":"2014","journal-title":"Nat Commun."},{"key":"2020112501165020300_CIT0034","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature17979","article-title":"Access of protective antiviral antibody to neuronal tissues requires CD4 T-cell help","volume":"533","author":"Iijima","year":"2016","journal-title":"Nature."},{"key":"2020112501165020300_CIT0035","doi-asserted-by":"crossref","first-page":"10956","DOI":"10.1073\/pnas.1603325113","article-title":"CD8 T cell-mediated killing of orexinergic neurons induces a narcolepsy-like phenotype in mice","volume":"113","author":"Bernard-Valnet","year":"2016","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2020112501165020300_CIT0036","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1002\/eji.200838023","article-title":"Blood CD8+ T cell responses against myelin determinants in multiple sclerosis and healthy individuals","volume":"38","author":"Berthelot","year":"2008","journal-title":"Eur J Immunol."},{"key":"2020112501165020300_CIT0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/sciimmunol.aao4013","article-title":"Islet-reactive CD8+ T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors","volume":"3","author":"Culina","year":"2018","journal-title":"Sci Immunol."},{"key":"2020112501165020300_CIT0038","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1750-3639.2003.tb00033.x","article-title":"Pattern of hypocretin (orexin) soma and axon loss, and gliosis, in human narcolepsy","volume":"13","author":"Thannickal","year":"2003","journal-title":"Brain Pathol."},{"key":"2020112501165020300_CIT0039","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/79690","article-title":"A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains","volume":"6","author":"Peyron","year":"2000","journal-title":"Nat Med."},{"key":"2020112501165020300_CIT0040","first-page":"1305","article-title":"Hypothalamic immunopathology in anti-Ma-associated diencephalitis with narcolepsy-cataplexy","volume":"70","author":"Dauvilliers","year":"2013","journal-title":"JAMA Neurol."},{"key":"2020112501165020300_CIT0041","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jaut.2013.06.010","article-title":"Passive transfer of narcolepsy: anti-TRIB2 autoantibody positive patient IgG causes hypothalamic orexin neuron loss and sleep attacks in mice","volume":"45","author":"Katzav","year":"2013","journal-title":"J Autoimmun."},{"key":"2020112501165020300_CIT0042","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.0001-2815.2004.00243.x","article-title":"Humanized animal models for autoimmune diseases","volume":"63","author":"Gregersen","year":"2004","journal-title":"Tissue Antigens."},{"key":"2020112501165020300_CIT0043","doi-asserted-by":"crossref","first-page":"e114361","DOI":"10.1371\/journal.pone.0114361","article-title":"Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for pandemrix-associated narcolepsy risk","volume":"9","author":"Vaarala","year":"2014","journal-title":"PLoS One."},{"key":"2020112501165020300_CIT0044","article-title":"Anti-Tribbles pseudokinase 2 (TRIB2)-immunization modulates hypocretin\/orexin neuronal functions","volume-title":"Sleep","author":"Tanaka","year":"2017"},{"key":"2020112501165020300_CIT0045","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1212\/WNL.0000000000001051","article-title":"Primary progressive narcolepsy type 1: the other side of the coin","volume":"83","author":"Pizza","year":"2014","journal-title":"Neurology."},{"key":"2020112501165020300_CIT0046","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsw010","article-title":"Temporal changes in the cerebrospinal fluid level of hypocretin-1 and histamine in narcolepsy","volume":"40","author":"Lopez","year":"2017","journal-title":"Sleep."},{"key":"2020112501165020300_CIT0047","doi-asserted-by":"crossref","first-page":"441","DOI":"10.5664\/jcsm.6500","article-title":"Intravenous immunoglobulin therapy in pediatric narcolepsy: a nonrandomized, open-label, controlled, longitudinal observational study","volume":"13","author":"Lecendreux","year":"2017","journal-title":"J Clin Sleep Med."},{"key":"2020112501165020300_CIT0048","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s00415-007-0594-8","article-title":"Response to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexy","volume":"254","author":"Fronczek","year":"2007","journal-title":"J Neurol."},{"key":"2020112501165020300_CIT0049","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1212\/WNL.0b013e3181bd1344","article-title":"Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment","volume":"73","author":"Dauvilliers","year":"2009","journal-title":"Neurology."},{"key":"2020112501165020300_CIT0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000389","article-title":"Long-term improvement after combined immunomodulation in early post-H1N1 vaccination narcolepsy","volume":"4","author":"Viste","year":"2017","journal-title":"Neurol Neuroimmunol NeuroInflamm."}],"container-title":["Sleep"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/sleep\/advance-article-pdf\/doi\/10.1093\/sleep\/zsaa055\/33014841\/zsaa055.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/sleep\/article-pdf\/43\/10\/zsaa055\/34498801\/zsaa055.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/sleep\/article-pdf\/43\/10\/zsaa055\/34498801\/zsaa055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T08:52:28Z","timestamp":1606294348000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/sleep\/article\/doi\/10.1093\/sleep\/zsaa055\/5813740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,28]]},"references-count":50,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,3,28]]},"published-print":{"date-parts":[[2020,10,13]]}},"URL":"https:\/\/doi.org\/10.1093\/sleep\/zsaa055","relation":{},"ISSN":["0161-8105","1550-9109"],"issn-type":[{"value":"0161-8105","type":"print"},{"value":"1550-9109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,3,28]]},"article-number":"zsaa055"}}